Drägerwerk AG & Co. KGaA/€DRW8
1D1W1MYTD1Y5YMAX
Capital at risk
About Drägerwerk AG & Co. KGaA
Drägerwerk AG & Co. KGaA is a German company specializing in medical and safety technology. The company provides a range of products and solutions in the fields of critical care, which includes anesthesia workstations, ventilators, and patient monitoring, as well as safety products for personal protection, gas detection, and firefighting. Dräger was founded in 1889 and is headquartered in Lübeck, Germany. Its operations extend globally, serving various industries such as healthcare, emergency services, mining, and industrial applications. Drägerwerk's strategic strength lies in its focus on high-quality, technologically advanced products and its long-standing expertise in medical and safety technologies.
- Ticker
- €DRW8
- Sector
- Health
- Primary listing
- XETRA
- Employees
- 16,009
- Headquarters
- Lübeck, Germany
- Website
- www.draeger.com
DRW8 Metrics
BasicAdvanced
€2B
10.16
€9.13
0.63
€2.21
2.38%
Price and volume
Market cap
€2B
Beta
0.63
52-week high
€88.20
52-week low
€50.00
Average daily volume
2.3K
Dividend rate
€2.21
Financial strength
Current ratio
2.051
Quick ratio
1.167
Long term debt to equity
0.186
Total debt to equity
0.234
Dividend payout ratio (TTM)
24.51%
Interest coverage (TTM)
12.43%
Profitability
EBITDA (TTM)
311.657
Gross margin (TTM)
45.74%
Net profit margin (TTM)
4.79%
Operating margin (TTM)
7.11%
Effective tax rate (TTM)
34.22%
Revenue per employee (TTM)
€220,000
Management effectiveness
Return on assets (TTM)
5.15%
Return on equity (TTM)
10.93%
Valuation
Price to earnings (TTM)
10.164
Price to revenue (TTM)
0.487
Price to book
1.21
Price to tangible book (TTM)
1.51
Price to free cash flow (TTM)
9.864
Free cash flow yield (TTM)
10.14%
Free cash flow per share (TTM)
9.408
Dividend yield (TTM)
2.38%
Forward dividend yield
2.38%
Growth
Revenue change (TTM)
6.37%
Earnings per share change (TTM)
71.51%
3-year revenue growth (CAGR)
2.96%
10-year revenue growth (CAGR)
3.47%
3-year earnings per share growth (CAGR)
61.03%
10-year earnings per share growth (CAGR)
25.53%
3-year dividend per share growth (CAGR)
128.61%
10-year dividend per share growth (CAGR)
28.15%
Bulls say / Bears say
Drägerwerk’s net sales climbed 7.7% currency-adjusted to €1.603 bn in H1 2026, with both its medical (+7.6% to €898 m) and safety (+7.8% to €706 m) divisions contributing to growth (Investing.com).
EBIT in H1 2026 more than tripled to €64 m from €20.4 m in H1 2025, boosting the group-wide EBIT margin to 4.0% from 1.3% (Investing.com).
Drägerwerk raised the lower end of its fiscal 2026 EBIT margin guidance to 5.5%–7.5% (from 5.0%–7.5%) following strong H1 results and tariff refunds, reflecting confidence in sustained profitability (Investing.com).
Order intake in the H1 2026 medical technology segment fell 3.7% currency-adjusted to €956.5 m, underscoring volatility in large project orders (Investing.com).
Full-year 2026 net sales guidance of a modest 2–6% currency-adjusted increase suggests tempered revenue expectations for the remainder of the year despite strong first-half momentum (Investing.com).
Data summarised monthly by Lightyear AI. Last updated on 1 Sept 2026.
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.